Healthcare >> CEO Interviews >> July 8, 2002
ELLIOT LEBOWITZ has served as President, Chief Executive Officer and as
a member of the Board of Directors of BioTransplant Incorporated since
April 1991. From 1985 to 1991, he served as Vice President for Research
and Development at C.R. Bard, Inc., directing internal and collaborative
research and development programs for Bard's Vascular Systems,
Cardiosurgery and Cardiopulmonary Divisions. From 1981 until 1985, Dr.
Lebowitz served as Director of Long Range Research and Development at
DuPont Corporation, developing immunopharmaceuticals. From 1977 until
1981, he served as Division Manager of the Medical Products Division of
New England Nuclear Corporation which developed, manufactured and sold
radiopharmaceuticals for in vivo diagnosis. Earlier in his career, Dr.
Lebowitz served at Brookhaven National Laboratories, where he developed
Thallium-201, a radiopharmaceutical for the diagnosis of coronary artery
disease. Dr. Lebowitz was a founder of Diagnostic Isotopes, Inc., a
radiopharmaceutical company which was subsequently acquired by Hoffman-
La Roche Inc., a pharmaceutical company. He was also a founder of
Procept, Inc., a biopharmaceutical company which focused on rational
drug design. He holds a BA from Columbia College and a PhD from Columbia
University. Profile
Incorporated?
Dr. Lebowitz: BioTransplant focuses on managing patients' immune
responses. In the case of autoimmune diseases or
